Patent · US Active

HIV vaccine formulation

US11603389B2 · kind B2 · utility

0Cited by
15References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 9, 2021
Grant dateMar 14, 2023
Priority date—
Expiry dateOct 9, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16134
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.